Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.

CD47:0.078 nM (EC50), CD47:0.152 nM (KD)

Methods: Raji, Jurkat, and Ramos cells were treated with Ligufalimab (0.1, 1, 10 µg/mL). Fluorescence microscopy and flow cytometry were used to detect Ligufalimab's promotion of macrophage-mediated tumor cell phagocytosis.
Results: Ligufalimab induced phagocytosis of Raji, Jurkat, and Ramos cells in a dose-dependent manner. [1]

Methods: Ligufalimab was intravenously administered at doses of 0.1 mg/kg and 1 mg/kg in Raji mouse xenograft tumor models, and at a dose of 0.2 mg/kg in MDA-MB-231 mouse xenograft tumor models to evaluate its antitumor efficacy.
Results: Ligufalimab demonstrated significant antitumor activity in both Raji and MDA-MB-231 xenograft tumor models without causing obvious body weight loss. [1]